|
Patients
|
Male or female patients with histologically or cytologicallyconfirmed squamous NSCLC
|
| |
Study participants must have not received chemotherapy treatment prior to first-line chemotherapy for NSCLC at the time of randomization in the study
|
|
Interventions
|
The study assesses a chemotherapy treatment in each of the study arms
|
| |
No limits are placed on the type of chemotherapy used
|
|
Outcomes
|
One or more of the following outcomes must be quantitatively reported in the publication: overall survival, progression-free survival, toxicity, or quality of life
|
| |
At least one of the required outcome variables must be reported separately for patients with advanced or metastatic (stage III/IV) NSCLC that is of squamous histology
|
|
Study design
|
RCTs
|
|
Time frame
|
1995 to present
|
|
Ineligibility criteria
|
|
Interventions
|
Not first-line treatment with first-line defined as patients with no prior exposure to chemotherapy
|
| |
Radiation therapy in the absence of concurrent chemotherapy in any treatment group
|
|
Study design
|
Review articles, news, editorials, commentaries
|
|
Time frame
|
Publication date prior to 1995
|
|
Matrix for patients with "squamous histology"
|
|
Squamous inclusion obvious in abstract?
|
Squamous results obvious in abstract?
|
Inclusion
|
Comments
|
|
Yes
|
Yes
|
Yes
| |
|
No
|
Yes
|
Yes
| |
|
Yes
|
No
|
Yes/No
|
Need full text to determine the inclusion
|
|
No
|
No
|
Yes/No
|
Need full text to determine the inclusion
|
|
Only non-squamous inclusion obvious in abstract?
|
Squamous results obvious in abstract?
|
Inclusion
|
Comments
|
|
Yes
|
Yes
|
Not possible case
| |
|
No
|
Yes
|
Yes
| |
|
Yes
|
No
|
No
| |
|
No
|
No
|
Yes/No
|
Need full text to determine the inclusion
|
|
Abstract mentions just NSCLC as inclusion?
|
Squamous results obvious in abstract?
|
Inclusion
|
Comments
|
|
Yes
|
Yes
|
Yes
| |
|
No
|
Yes
|
Yes/No
|
This may be multisite cancer study, need full text to determine the inclusion
|
|
Yes
|
No
|
Yes/No
|
Need full text to determine the inclusion
|
|
No
|
No
|
Noise in the search
|
Need full text to determine the inclusion
|
|
Multiple cancers
|
If mentions lung cancer
|
Yes/No
|
Need full text to determine the inclusion
|
| |
If does not mention any specific tumor types
|
Yes/No
|
Need full text to determine the inclusion
|
| |
If only mentions breast cancer or other types and does not mention lung cancer
|
Noise in the search
| |
|
Matrix for "not first-line treatment"
|
|
Condition
|
Line of treatment to be considered
|
Inclusion
|
Comments
|
|
Naïve NSCLC patients
|
1st
|
Yes
| |
|
First- or front-line treatment
|
1st
|
Yes
| |
|
Untreated NSCLC patients
|
1st
|
Yes
| |
|
Metastatic chemo-naïve NSCLC patients
|
1st
|
Yes
| |
|
Chemo-naïve NSCLC patients
|
1st
|
Yes
| |
|
Second-line treatment
|
2nd
|
No
| |
|
(Rx)-resistant NSCLC patients
|
2nd
|
No
| |
|
Recurrent or progressive disease
|
2nd
|
No
| |
|
(Rx)-responder/non-responder patients
|
2nd
|
No
| |
|
If no clear information on line of treatment
|
NA
|
Yes/No
|
Need full text to determine the inclusion
|
